Pursuing Charlene's Dream

Article

Oncology nursing is more than just a job to Barbara Bittner, RN, OCN.

Barbara Bittner, RN, OCN, is an oncology nurse navigator at AdventHealth in Florida. But to her, nursing is much more than just a career. Bittner cares deeply for all of her patients, and even helped establish Charlene's Dream, a resource center for women with cancer, after her friend and Colleague, Charlene, passed away from the disease.

Recent Videos
5 experts in this video
5 experts in this video
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
White line illustration on a dark blue background of a clipboard that says "FDA" at the top next to a shield with a checkmark on it

Oncology Drugs Approved by the FDA in March 2025

Bridget Hoyt
April 1st 2025
Article

The FDA approved treatments in various gastrointestinal and genitourinary cancers in March.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Image of an ovarian cancer cell

Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer

Jax DiEugenio
March 31st 2025
Article

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Rendering of red blood cells with multiple myeloma

Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM

Roman Fabbricatore
March 30th 2025
Article

Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.

Illustration of a liver in front of a document and medical icons with a magnifying glass over the liver

Camrelizumab Plus Rivoceranib Receives Second CRL in HCC

Roman Fabbricatore;Russ Conroy
March 29th 2025
Article

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in camrelizumab/rivoceranib for advanced HCC.